Blog

Recently, foreign pharmaceutical makers such as AbbVie, AstraZeneca, Novartis, Sanofi, and Roche slashed the prices of a large number of drugs sold in China, the world’s second largest drug market.

China and the European Union (EU) have been discussing a bilateral investment treaty (BIT) for a long time. Indeed, the two sides held their 21^st round of China-EU BIT negotiations in June 2019.

These days “Washington” seems to think little of Chinese investment. It does not matter if it is Chinese foreign direct investment (FDI) in the United States (US) or US FDI in China. Importantly, the core concerns in each case are different.

In my March blog, I expressed skepticism about China’s financial sector reform due to Beijing’s myriad political and economic reasons for maintaining control of the banking, insurance, and securities sectors.

A quarter of Japanese manufacturing is done overseas with the subsidiaries of Japanese multinational corporations (MNCs) venturing overseas to extend global value chains (GVCs) that begin in Japan. Under the resulting structure, the majority of Japanese manufacturing exports head towards overseas subsidiaries with capital ties to headquarters in Japan.